國家衛生研究院 NHRI:Item 3990099045/14506
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 911444      線上人數 : 918
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14506


    題名: Multi-kinase inhibitors for the treatment of asymptomatic radioactive Iodine-refractory differentiated thyroid cancer: Global non-interventional study (RIFTOS MKI)
    作者: Brose, M;Smit, J;Lin, CC;Tori, M;Bowles, D;Worden, F;Shen, DH;Huang, SM;Tsai, HJ;Alevizaki, M;Peeters, RP;Takahashi, S;Rumyantsev, P;Guan, R;Babajanyan, S;Ozgurdal, K;Sugitani, I;Pitoia, F;Lamartina, L
    貢獻者: National Institute of Cancer Research
    摘要: BACKGROUND: Sorafenib and lenvatinib are multi-kinase inhibitors (MKI) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective of this study was to evaluate time to symptomatic progression (TTSP) in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. METHODS: International, prospective, open-label, non-interventional cohort study (NCT02303444). Eligible patients had asymptomatic, progressive RAI-R DTC, with ≥1 lesion ≥1 cm in diameter and life expectancy ≥6 months. The decision to treat with an MKI was at the treating physician's discretion. Primary endpoint was TTSP from study entry. Two cohorts were evaluated: patients for whom a decision to initiate an MKI was made at study entry (Cohort 1) and patients for whom there was a decision not to initiate an MKI at study entry (Cohort 2). Cohorts were compared descriptively. RESULTS: The full analysis set (FAS) comprised 647 patients from 19 countries. The median duration of observation was 35.5 months (range <1-59.4). Of 344 MKI-treated patients, 209 received sorafenib, 191 received lenvatinib, and 19 received another MKI at some point. Median TTSP was 55.4 months (interquartile range [IQR] 18.6-not estimable [NE]) overall, 55.4 months (IQR 15.2-NE) in Cohort 1 (n=169), and 51.4 months (IQR 20.0-NE) in Cohort 2 (n=478). TTSP ≥36 months was achieved in 64.5% of patients overall, 59.5% of patients in Cohort 1, and 66.4% of patients in Cohort 2. Median overall survival (OS) from classification as RAI-R was 167 months and median PFS from start of MKI therapy was 19.2 months and from start of sorafenib therapy 16.7 months. Among sorafenib-treated patients, 70% had dose modifications, 35% had a dose reduction, 89% experienced ≥1 treatment-emergent adverse event (TEAE), and 82% experienced ≥1 drug-related TEAE. CONCLUSION: This real-world study provides valuable insight into outcomes in patients with asymptomatic, progressive RAI-R DTC under observation or MKI treatment. TTSP in the FAS provides insight into the current prognosis for patients with RAI-R DTC in the era of MKIs.
    日期: 2022-09
    關聯: Thyroid. 2022 Sep;32(9):1059-1068.
    Link to: http://dx.doi.org/10.1089/thy.2022.0061
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1050-7256&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000855923000001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85138450554
    顯示於類別:[蔡慧珍] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML172檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋